Zalgen Labs, LLC
Germantown Innovation Center
20271 Goldenrod Lane, Suite 2083
Zalgen has core competency in the development of multiple platforms for generation of high quality recombinant proteins from difficult-to-express genes. Our proven approaches are supported by the successful development of first-to-field-use rapid diagnostic tests for Lassa hemorrhagic fever (LHF) by a consortium of academic, institutional, and biotechnology entities, led by one of our founders, Dr. Robert F. Garry (http://tulane.edu/som/cancer/robert-garry.cfm). These diagnostics are revolutionizing the understanding of epidemiological, immunological, and basic research notions in LHF, thus contributing to dramatic improvements in the management and successful outcome of this viral disease.
Founders: Robert F. Garry and Luis M. Branco
Please click here for Zalgen Labs job opportunities.
Please click here for clinical trial information.
FOLLOW ZALGEN LABS: